Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Feb 23, 2017 • 4:01 PM EST
Ligand Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 14, 2017 • 4:30 PM EST
Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform
Feb 13, 2017 • 4:30 PM EST
Reminder: Ligand to Host Analyst Day on February 28th in New York City
Feb 23, 2017 • 4:30pm EST
See all events
Nov 9, 2016 • 1:00pm EST
New York, NY
Nov 3, 2016 • 4:30pm EST
Feb 28, 2017 • 10:00am EST
Viking announces funding for important new trial of VK2809/TRb in GSD1a; trial to initiate in 2017 https://t.co/CX1I1KXFCc
$VKTX announces initial results from in vivo proof-of-concept study of VK2809 in Glycogen Storage Disease Ia https://t.co/RVpRVoALfa
$ALDX announces first patient enrolled in allergic conjunctivitis Phase 2b clinical trial https://t.co/KlRGunMJc3